You are here: Industry Insights > BenevolentAI

News List

BenevolentAI and AstraZeneca expand drug discovery partnership Pharmaceutical-Technology
January 17, 2022
The companies collaborated initially in 2019 to use AI and machine learning to develop new therapies for CKD and IPF.
BenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca's portfolio prnasia
December 17, 2021
BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added a novel target for idiopathic pulmonary fibrosis (IPF), discovered using BenevolentAI's platform, to its drug development portfolio.
Drug developer BenevolentAI enters SPAC merger deal with Odyssey Pharmaceutical-Technology
December 08, 2021
UK-based clinical-stage artificial intelligence (AI) drug discovery firm BenevolentAI has signed a definitive agreement for a business combination with the special-purpose acquisition company (SPAC) Odyssey Acquisition.
BenevolentAI's Platform-Derived Hypothesis for COVID-19 Treatment Validated in NIAID Trial americanpharmaceuticalreview
September 22, 2020
BenevolentAI has confirmed data released from a large scale randomized clinical trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), further validating its AI-derived hypothesis for baricitinib as a treatment for COVID-19
AstraZeneca forms drug discovery alliance with BenevolentAI pharmaceutical-technology
May 05, 2019
AstraZeneca has partnered with artificial intelligence (AI) company BenevolentAI to develop treatments for chronic kidney disease and idiopathic pulmonary fibrosis.
UK biotech ‘unicorn’ BenevolentAI raises cash for further expansion pharmaphorum
April 24, 2018
BenevolentAI has raised a further $115 million from new and existing investors in a move that increases its value to more than $2 billion.
UK biotech ‘unicorn’ BenevolentAI raises cash for further expansion pharmaphorum
April 23, 2018
BenevolentAI has raised a further $115 million from new and existing investors in a move that increases its value to more than $2 billion.
Charities link with BenevolentAI to discover new AMD therapies pharmatimes
March 16, 2018
BenevolentAI has teamed up with Action Against AMD* to find treatments and a potential cure for age-related macular degeneration, the leading cause of blindness in the UK.